You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 2, February 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, NEW ORLEANS, LA, MAY 22 TO MAY 25, 1988-Part II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Prolongation of Survival of Nude Mice Bearing Human Colon Cancer

Treatment With Yttrium 90—Labeled Anti—Carcinoembryonic Antigen Antibody

David M. Hyams, MD; Jose M. Esteban, MD; Barbara G. Beatty, PhD; Philip M. Wanek, RPh; J. David Beatty, MD

Arch Surg. 1989;124(2):175-179.


Abstract

• Nude mice bearing diffuse intraperitoneal carcinomatosis of the human colon cancer cell line LS174T were treated with an anti–carcinoembryonic antigen monoclonal antibody (MAB) that was labeled with yttrium 90 (90Y-ZCE025). Control animals were either untreated or treated with nonspecific99Y-MAB (90Y-96.5c). The median survival (MS) for untreated animals was 26 days. The MS for specific and nonspecific therapy that consisted of 120 µCi of90Y-MAB was 69 and 34 days, respectively. No significant improvement in the MS was observed with a second 120-µCi administration of90Y-MAB given two weeks later. A decreased MS was observed with 80 µCi of90Y-MAB given every four days for three cycles. In each category, specific therapy had a significant advantage over nonspecific therapy in increased effectiveness and decreased toxicity. The90Y-ZCE025 therapy gave an increased life span of almost 200%. The therapeutic effects with different dosing regimens have important implications for treatment planning.

(Arch Surg 1989;124:175-179)



Author Affiliations

From the Departments of General Oncologic Surgery (Drs Hyams, B. G. Beatty, and J. D. Beatty) and Anatomic Pathology (Dr Esteban), City of Hope National Medical Center, Duarte, Calif, and Hybritech Inc, San Diego (Mr Wanek).


Footnotes

Accepted for publication Nov 29, 1988.

Read before the Annual Meeting of the Society of Surgical Oncology, New Orleans, May 23, 1988.

Reprint requests to Department of General Oncologic Surgery, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010 (Dr J. D. Beatty).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radioimmunotherapy of Human Colon Cancer in Nude Mice
Buras et al.
Arch Surg 1990;125:660-664.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.